NCT04378543View on ClinicalTrials.gov

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

April 30, 2022

Study Completion Date

October 31, 2023

Conditions
Degenerative Spondylolisthesis
Interventions
BIOLOGICAL

ART352-L

recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures

Trial Locations (3)

43210

RECRUITING

Wexner Medical Center, The Ohio State University, Columbus

55905

RECRUITING

Mayo Clinic, Rochester

90033

RECRUITING

Keck School of Medicine, University of Southern California, Los Angeles

Sponsors
All Listed Sponsors
lead

Ankasa Regenerative Therapeutics, Inc.

INDUSTRY